Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases

Nutrition Reviews

Volumn 71, Issue 8, 2013, Pages 562-572

  Nagaraju, Ganji Purnachandra ^a   Zafar, Syed F ^a   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chronic disease; Genistein; Soy isoflavones

Indexed keywords

CYCLOOXYGENASE 2; GENISTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; ISOFLAVONE DERIVATIVE; MATRIX METALLOPROTEINASE; PROSTAGLANDIN E2; SOMATOMEDIN;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CELIAC DISEASE; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DIET; DNA DAMAGE; DRUG BLOOD LEVEL; DYSLIPIDEMIA; ENDOMETRIUM CANCER; ENTERITIS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; METASTASIS; NEOPLASM; NEUROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS DISEASE; PLEIOTROPY; PROSTATE ADENOCARCINOMA; REFLUX ESOPHAGITIS; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER;

CANCER; CHRONIC DISEASE; GENISTEIN; SOY ISOFLAVONES;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; GENISTEIN; HUMANS; INFLAMMATION; ISOFLAVONES; METABOLIC DISEASES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84880602076     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12044     Document Type: Article

References (149)

1. Adlercreutz CH, Goldin BR, Gorbach SL, etal. Soybean phytoestrogen intake and cancer risk. J Nutr. 1995;125(Suppl 3):S757-S770.
2. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr. 1999;129:S758-S767.
3. Badger TM, Ronis MJ, Simmen RC, etal. Soy protein isolate and protection against cancer. J Am Coll Nutr. 2005;24:S146-S149.
4. Nechuta SJ, Caan BJ, Chen WY, etal. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123-132.
5. Hwang YW, Kim SY, Jee SH, etal. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer. 2009;61:598-606.
6. Martínez ME. Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Cancer Res. 2005;166:177-211.
7. Xia X, Weng J. Targeting metabolic syndrome: candidate natural agents. J Diabetes. 2010;2:243-249.
8. Valsecchi AE, Franchi S, Panerai AE, etal. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol. 2011;650:694-702.
9. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7:1003-1015.
10. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143:550-563.
11. Perkin AG, Newbury FG. The colouring matters contained in dyer's broom (Genista tinctoria) and heather (Calluna vulgaris). J Chem Soc. 1899;75:830-839.
12. Tůmová L, Tůma J. The effect of UV light on isoflavonoid production in Genista tinctoria culture in vitro. Acta Physiol Plant. 2011;33:635-640.
13. Kuiper GG, Lemmen JG, Carlsson B, etal. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252-4263.
14. Szkudelska K, Nogowski L. Genistein - a dietary compound inducing hormonal and metabolic changes. J Steroid Biochem Mol Biol. 2007;105:37-45.
15. McCarty MF. Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses. 2006;66:1093-1114.
16. Takimoto CH, Glover K, Huang X, etal. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1213-1221.
17. Wannamethee SG, Shaper AG, Lennon L, etal. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-2650.
18. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:836-842.
19. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8:483-494.
20. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc. 2001;60:91-106.
21. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915-928.
22. Clemmons DR, Busby WH, Arai T, etal. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6:357-366.
23. Ullrich A, Bell JR, Chen EY, etal. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985;313:756-761.
24. Belfiore A, Frasca F, Pandini G, etal. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586-623.
25. Benyoucef S, Surinya KH, Hadaschik D, etal. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J. 2007;403:603-613.
26. LeRoith D. Insulin-like growth factor I receptor signaling - overlapping or redundant pathways? Endocrinology. 2000;141:1287-1288.
27. Frasca F, Pandini G, Scalia P, etal. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19:3278-3288.
28. Vigneri P, Frasca F, Sciacca L, etal. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103-1123.
29. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591.
30. Yang XF, Beamer WG, Huynh H, etal. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996;56:1509-1511.
31. Zhang L, Zhou W, Velculescu VE, etal. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268-1272.
32. Venkateswaran V, Haddad AQ, Fleshner NE, etal. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99:1793-1800.
33. Algire C, Amrein L, Bazile M, etal. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;30:1174-1182.
34. Ma J, Giovannucci E, Pollak M, etal. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546-553.
35. Harrela M, Koistinen H, Kaprio J, etal. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996;98:2612-2615.
36. Algire C, Amrein L, Zakikhani M, etal. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010;17:351-360.
37. Boyle P, Boniol M, Koechlin A, etal. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107:1608-1617.
38. Forte V, Pandey A, Abdelmessih R, etal. Obesity, diabetes, the cardiorenal syndrome, and risk for cancer. Cardiorenal Med. 2012;2:143-162.
39. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer. 2012;19:1-8.
40. Lee J, Ju J, Park S, etal. Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells. Nutr Cancer. 2012;64:153-162.
41. Kim EJ, Shin HK, Park JH. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of genistein. J Med Food. 2005;8:431-438.
42. Ascencio C, Torres N, Isoard-Acosta F, etal. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr. 2004;134:522-529.
43. Cheng SY, Shaw NS, Tsai KS, etal. The hypoglycemic effects of soy isoflavones on postmenopausal women. J Womens Health (Larchmt). 2004;13:1080-1086.
44. Villa P, Costantini B, Suriano R, etal. The differential effect of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women: relationship with the metabolic status. J Clin Endocrinol Metab. 2009;94:552-558.
45. Mackowiak P, Nogowski L, Nowak KW. Effect of isoflavone genistein on insulin receptors in perfused liver of ovariectomized rats. J Recept Signal Transduct Res. 1999;19:283-292.
46. Naaz A, Yellayi S, Zakroczymski MA, etal. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology. 2003;144:3315-3320.
47. Cederroth CR, Vinciguerra M, Gjinovci A, etal. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes. 2008;57:1176-1185.
48. Ronis MJ, Chen Y, Badeaux J, etal. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr. 2009;139:1431-1438.
49. Kim MH, Park JS, Seo MS, etal. Genistein and daidzein repress adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via Wnt/beta-catenin signalling or lipolysis. Cell Prolif. 2010;43:594-605.
50. Bitto A, Altavilla D, Bonaiuto A, etal. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. J Endocrinol. 2009;200:367-376.
51. Calle EE, Rodriguez C, Walker-Thurmond K, etal. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
52. Anderson GL, Neuhouser ML. Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res (Phila). 2012;5:515-521.
53. Sorbye H, Welin S, Langer SW, etal. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152-160.
54. Healy LA, Ryan AM, Carroll P, etal. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010;22:281-288.
55. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-2180.
56. Paz-Filho G, Lim EL, Wong ML, etal. Associations between adipokines and obesity-related cancer. Front Biosci. 2011;16:1634-1650.
57. Kelesidis T, Kelesidis I, Chou S, etal. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93-100.
58. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-355.
59. Giovannucci E, Harlan DM, Archer MC, etal. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.
60. Szkudelska K, Nogowski L, Szkudelski T. Genistein, a plant-derived isoflavone, counteracts the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol. 2008;109:108-114.
61. Park HJ, Della-Fera MA, Hausman DB, etal. Genistein inhibits differentiation of primary human adipocytes. J Nutr Biochem. 2009;20:140-148.
62. Szkudelski T, Nogowski L, Pruszynska-Oszmalek E, etal. Genistein restricts leptin secretion from rat adipocytes. J Steroid Biochem Mol Biol. 2005;96:301-307.
63. Llaneza P, Gonzalez C, Fernandez-Inarrea J, etal. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine. 2011;18:245-250.
64. Penza M, Montani C, Romani A, etal. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology. 2006;147:5740-5751.
65. LeRoith D. Can endogenous hyperinsulinaemia explain the increased risk of cancer development and mortality in type 2 diabetes: evidence from mouse models. Diabetes Metab Res Rev. 2010;26:599-601.
66. Kling J. Inhaled insulin's last gasp? Nat Biotechnol. 2008;26:479-480.
67. Fu Z, Gilbert ER, Pfeiffer L, etal. Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes. Appl Physiol Nutr Metab. 2012;37:480-488.
68. Fu Z, Zhang W, Zhen W, etal. Genistein induces pancreatic β-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinology. 2010;151:3026-3037.
69. Baluchnejadmojarad T, Roghani M. Chronic administration of genistein improves aortic reactivity of streptozotocin-diabetic rats: mode of action. Vascul Pharmacol. 2008;49:1-5.
70. Zhong WW, Liu Y, Li CL. Mechanisms of genistein protection on pancreas cell damage in high glucose condition. Intern Med. 2011;50:2129-2134.
71. Yang W, Wang S, Li L, etal. Genistein reduces hyperglycemia and islet cell loss in a high-dosage manner in rats with alloxan-induced pancreatic damage. Pancreas. 2011;40:396-402.
72. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
73. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32:1119-1136.
74. Velayos F. Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. Expert Rev Gastroenterol Hepatol. 2008;2:817-825.
75. Soetikno RM, Lin OS, Heidenreich PA, etal. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54.
76. Ekstrom K, Hjalgrim H, Brandt L, etal. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48:963-970.
77. Chen YJ, Chang YT, Wang CB, etal. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010;123:e1151-e1156.
78. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100.
79. Lagergren J, Bergstrom R, Lindgren A, etal. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
80. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721-732.
81. Kim R, Weissfeld JL, Reynolds JC, etal. Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1997;6:369-377.
82. Bahmanyar S, Montgomery SM, Hillert J, etal. Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2009;72:1170-1177.
83. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology. 2004;23:224-227.
84. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-767.
85. Sakaguchi S, Yamaguchi T, Nomura T, etal. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.
86. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276-285.
87. Zhuang JC, Lin C, Lin D, etal. Mutagenesis associated with nitric oxide production in macrophages. Proc Natl Acad Sci U S A. 1998;95:8286-8291.
88. Hofseth LJ, Saito S, Hussain SP, etal. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A. 2003;100:143-148.
89. Hussain SP, He P, Subleski J, etal. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res. 2008;68:7130-7136.
90. Hedegaard CJ, Krakauer M, Bendtzen K, etal. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008;125:161-169.
91. Juedes AE, Hjelmstrom P, Bergman CM, etal. Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol. 2000;164:419-426.
92. Castro SB, Junior CO, Alves CC, etal. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment. Int Immunopharmacol. 2012;12:465-470.
93. Gao F, Wei D, Bian T, etal. Genistein attenuated allergic airway inflammation by modulating the transcription factors T-bet, GATA-3 and STAT-6 in a murine model of asthma. Pharmacology. 2012;89:229-236.
94. Zhang Y, Dong J, He P, etal. Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis. Inflammation. 2012;35:377-387.
95. Hamalainen M, Nieminen R, Asmawi MZ, etal. Effects of flavonoids on prostaglandin E2 production and on COX-2 and mPGES-1 expressions in activated macrophages. Planta Med. 2011;77:1504-1511.
96. Blay M, Espinel AE, Delgado MA, etal. Isoflavone effect on gene expression profile and biomarkers of inflammation. J Pharm Biomed Anal. 2010;51:382-390.
97. Seibel J, Molzberger AF, Hertrampf T, etal. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur J Nutr. 2009;48:213-220.
98. Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996;7:1345-1351.
99. Pagliacci MC, Smacchia M, Migliorati G, etal. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer. 1994;30A:1675-1682.
100. Landstrom M, Zhang JX, Hallmans G, etal. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate. 1998;36:151-161.
101. Zhou JR, Gugger ET, Tanaka T, etal. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628-1635.
102. Li D, Yee JA, McGuire MH, etal. Soybean isoflavones reduce experimental metastasis in mice. J Nutr. 1999;129:1075-1078.
103. Singh AV, Franke AA, Blackburn GL, etal. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res. 2006;66:1851-1858.
104. Refsum S. Genetic aspects of epilepsy. Tidsskr Nor Laegeforen. 1974;94:1976-1978.
105. Shyong EQ, Lu Y, Lazinsky A, etal. Effects of the isoflavone 4′, 5, 7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. Carcinogenesis. 2002;23:317-321.
106. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem. 2007;18:427-442.
107. Casagrande F, Darbon JM. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res. 2000;258:101-108.
108. Ismail IA, Kang KS, Lee HA, etal. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol. 2007;575:12-20.
109. Ouyang G, Yao L, Ruan K, etal. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int. 2009;33:1237-1244.
110. Choi YH, Zhang L, Lee WH, etal. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol. 1998;13:391-396.
111. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998;32:123-131.
112. WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer. 1998;31:184-191.
113. Alhasan SA, Pietrasczkiwicz H, Alonso MD, etal. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer. 1999;34:12-19.
114. Touny LH, Banerjee PP. Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. Prostate. 2006;66:1542-1555.
115. Li Y, Upadhyay S, Bhuiyan M, etal. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999;18:3166-3172.
116. Banerjee S, Zhang Y, Wang Z, etal. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer. 2007;120:906-917.
117. Banerjee S, Zhang Y, Ali S, etal. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005;65:9064-9072.
118. Banerjee S, Li Y, Wang Z, etal. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008;269:226-242.
119. Kazi A, Daniel KG, Smith DM, etal. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003;66:965-976.
120. Yeh TC, Chiang PC, Li TK, etal. Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult. Biochem Pharmacol. 2007;73:782-792.
121. Lee CH, Jeon YT, Kim SH, etal. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007;29:19-35.
122. Alhasan SA, Ensley JF, Sarkar FH. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol. 2000;16:333-338.
123. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999;35:167-174.
124. Natarajan K, Manna SK, Chaturvedi MM, etal. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-κB, degradation of IκBα, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys. 1998;352:59-70.
125. Valachovicova T, Slivova V, Bergman H, etal. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-κB/AP-1-dependent and -independent pathways. Int J Oncol. 2004;25:1389-1395.
126. Schonthaler HB, Guinea-Viniegra J, Wagner EF. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis. 2011;70(Suppl 1):i109-i112.
127. Li Y, Ellis KL, Ali S, etal. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004;28:e90-e95.
128. Ruiz PA, Haller D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-κB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr. 2006;136:664-671.
129. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.
130. Li Y, Sarkar FH. Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res. 2002;8:2369-2377.
131. El Touny LH, Banerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis. 2007;28:1710-1717.
132. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726-735.
133. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 2000;19:6594-6599.
134. Davis JN, Kucuk O, Djuric Z, etal. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med. 2001;30:1293-1302.
135. Huang X, Chen S, Xu L, etal. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 2005;65:3470-3478.
136. Xu L, Bergan RC. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol Pharmacol. 2006;70:869-877.
137. Fotsis T, Pepper M, Adlercreutz H, etal. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr. 1995;125(Suppl 3):S790-S797.
138. Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr. 1998;68(Suppl 6):S1418-S1425.
139. Sasamura H, Takahashi A, Miyao N, etal. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002;86:768-773.
140. Guo Y, Wang S, Hoot DR, etal. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem. 2007;18:408-417.
141. Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor - HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 2012;19:90-97.
142. Molinie B, Georgel P. Genetic and epigenetic regulations of prostate cancer by genistein. Drug News Perspect. 2009;22:247-254.
143. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics. 2010;1:101-116.
144. Majid S, Kikuno N, Nelles J, etal. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 2008;68:2736-2744.
145. Kikuno N, Shiina H, Urakami S, etal. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer. 2008;123:552-560.
146. Wang Z, Chen H. Genistein increases gene expression by demethylation of WNT5a promoter in colon cancer cell line SW1116. Anticancer Res. 2010;30:4537-4545.
147. INK4a, RARβ, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005;11(19 Pt 1):7033-7041.
148. Fang MZ, Jin Z, Wang Y, etal. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol. 2005;26:615-622.
149. Li H, Xu W, Huang Y, etal. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. Int J Mol Med. 2012;30:1081-1086.